WAVE Life Sciences

67 articles with WAVE Life Sciences

• 

  Wave Life Sciences Shares Plunge After Mixed Results from Huntington’s Trial

  12/31/2019

  Although the reduction in mHTT with the drug compared to placebo was statistically significant, there was no change in total huntingtin protein (tHTT) compared to placebo.

• Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

  12/30/2019

  WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo

• Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

  12/16/2019

  Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study.

• Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/5/2019

  Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced financial results for the third quarter ended September 30, 2019 and provided a business update.

• 

  What Sarepta's DMD Rejection Might Mean for Other Biotechs

  8/21/2019

  Although a definite blow to Sarepta, this may have negative implications for other companies working to develop therapies for DMD. This includes Wave Life Sciences and Solid Biosciences.
• 

  For Life Science Companies in the Bay State, Project Onramp Opens up Internship Opportunities

  1/29/2019

  The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc...
• 

  Wave Life Sciences Enters FDA's Clinical Trial Pilot Program to Develop DMD Drug

  1/15/2019

  Wave Life Sciences is working to get its nucleic acid treatment, suvodirsen, for Duchenne muscular dystrophy (DMD) approved. DMD is a rare muscle-wasting disease that affects mostly boys, about 15,000 in the U.S.
• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.

• Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)

  12/6/2018

  Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial.

• Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

  10/9/2018

  Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290

• Takeda Partners With Wave Life Sciences

  2/20/2018

  Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd.

• Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND

  12/11/2017

  Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD.

• Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/9/2017

  Wave reported a net loss of $26.1 million for the third quarter of 2017, as compared to a net loss of $17.5 million for the third quarter of 2016.

• Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy

  11/6/2017

  This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.

• 

  Cambridge-Based Wave Life Sciences Expands Into New Facility Designed to House Up to 200 Employees

  10/27/2017

  Wave Life Sciences has officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.

• WAVE Life Sciences To Present At The Jefferies Gene Technology Investor Summit

  10/12/2017

• WAVE Life Sciences Announces Publication Of Paper In Nature Biotechnology Establishing The Importance Of Stereochemical Purity In Oligonucleotide Drug Design

  8/22/2017

• WAVE Life Sciences Reports Second Quarter 2017 Financial Results And Provides Business Update

  8/9/2017

• WAVE Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease

  7/17/2017

• ReadCoor And WAVE Life Sciences Initiate Research Collaboration

  6/8/2017